An #intranasal adjuvanted, recombinant #influenza A/ #H5 #vaccine primes against diverse #H5N1 clades: a phase I trial, https://etidiohnew.blogspot.com/2025/11/an-intranasal-adjuvanted-recombinant.html
An #intranasal adjuvanted, recombinant #influenza A/ #H5 #vaccine primes against diverse #H5N1 clades: a phase I trial

A single-dose #intranasal #immunization with a novel #bat #influenza A virus-vectored #MERS #vaccine provides effective protection against lethal MERS-CoV challenge, https://etidiohnew.blogspot.com/2025/07/a-single-dose-intranasal-immunization.html
A single-dose #intranasal #immunization with a novel #bat #influenza A virus-vectored #MERS #vaccine provides effective protection against lethal MERS-CoV challenge

Immunogenicity and protective #efficacy of an #intranasal NA-based #influenza virus #vaccine adjuvanted ...

#Intranasal #hemagglutinin protein #boosters induce robust mucosal #immunity and cross-protection against #influenza A viral challenge

Source: BioRxIV, AbstractLicensed parenteral influenza vaccines induce systemic antibody responses and alleviate disease severity but do not efficiently prevent viral entry and transmission due to the lack of local mucosal immune responses. Here, we describe intranasal booster strategy with unadjuvanted recombinant hemagglutinin (HA)…

https://etidioh.wordpress.com/2024/10/15/intranasal-hemagglutinin-protein-boosters-induce-robust-mucosal-immunity-and-cross-protection-against-influenza-a-viral-challenge/

#Intranasal #hemagglutinin protein #boosters induce robust mucosal #immunity and cross-protection against #influenza A viral challenge

Source: BioRxIV, AbstractLicensed parenteral influenza vaccines induce systemic antibody responses and alleviate disease severity but do not efficiently prevent viral entry and transmission due to …

ETIDIoH

A single-dose #intranasal live-attenuated codon deoptimized #vaccine provides broad #protection against #SARS-CoV-2 and its #variants, Nat Commun.: https://www.nature.com/articles/s41467-024-51535-y

Current SARS-CoV-2 vaccines require several injections for optimal immune protection. Here, the authors report an intranasal live-attenuated vaccine that induces long-term immunity following a single dose and protects from SARS-CoV-2 wildtype and variants in non-human primate and small animal models.

A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants - Nature Communications

Current SARS-CoV-2 vaccines require several injections for optimal immune protection. Here, the authors report an intranasal live-attenuated vaccine that induces long-term immunity following a single dose and protects from SARS-CoV-2 wildtype and variants in non-human primate and small animal models.

Nature

#Intranasal administration of 8-valent next-generation #flu #vaccine elicits protective immune responses vs seasonal and #prepandemic viruses, J Virol.: https://journals.asm.org/doi/full/10.1128/jvi.00354-24?af=R

8-valent COBRA vaccine elicited #antibodies that recognized a broad panel of strains representing different subtypes, & these vaccinated animals were protected vs flu virus challenges. This study demonstrated that mixture of 8 COBRA HA/NA proteins mixed with an intranasal adjuvant is a promising candidate vaccine.

#Intranasal M2SR (#M2-deficient Single Replication) #Influenza #Vaccine Induces Broadly Reactive #Mucosal #Antibody Production in Adults, J Infect Dis.: https://academic.oup.com/jid/advance-article-abstract/doi/10.1093/infdis/jiae361/7714804?redirectedFrom=fulltext&utm_source=advanceaccess&utm_campaign=jid&utm_medium=email

These data suggest that M2SR induces broadly cross-reactive mucosal immune responses which may provide better protection against drifted and newly emerging influenza strains.

Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults

Intranasal H3N2 M2SR vaccine induced cross-reactive mucosal IgA antibodies against a panel of H3N2 hemagglutinins ranging from 1968 to 2014 in adults indep

OUP Academic
An intranasal live-attenuated SARS-CoV-2 vaccine limits virus transmission - Nature Communications

In this study, the authors evaluated the protective capacity of a mucosal, live-attenuated SARS-CoV-2 vaccine and show that it induces systemic and mucosal humoral immunity, protects from clinical disease symptoms, and prevents virus transmission in hamsters more efficiently than an intramuscular mRNA vaccine.

Nature
This could be pretty interesting: AstraZeneca, which makes the #intranasal flu vaccine #FluMist, has applied to #FDA to allow the vaccine to be administered at home, by adults eligible to get it or old enough to give it to eligible kids. Decision pending; watch this space. https://www.statnews.com/2023/10/24/astrazeneca-maker-of-flumist-seeks-to-allow-at-home-administration-of-vaccine/
AstraZeneca, maker of FluMist, seeks to allow at-home administration of vaccine

People eligible to use the only needle-free flu vaccine available in the United States may be able, next year, to give it to themselves or to eligible children at home.

STAT